强骨胶囊治疗原发性骨质疏松症的系统评价  

A systematic review of Qianggu capsule for treatment of primary osteoporosis

作　　者：陈友浩[1] 李章华[1] 崔西龙[1] 柳铭[1] 刘天舒[1] 肖思杰[1] 

机构地区：[1]武汉大学人民医院骨一科,武汉430060

出　　处：《中国骨质疏松杂志》2010年第9期652-654,665,共4页Chinese Journal of Osteoporosis

摘　　要：目的系统评价强骨胶囊治疗原发性骨质疏松症的疗效和安全性。方法通过计算机检索最近10年关于强骨胶囊治疗骨质疏松症的随机对照试验研究文献,按标准纳入和排除文献后提取资料,采用循证医学Meta分析法对骨密度、骨痛、并发症等疗效和安全性进行系统评价。结果共纳入文献5篇,Meta分析发现,原发性骨质疏松症患者骨密度应用强骨胶囊治疗前后有统计学差异(P=0.02),对比传统药物改善骨痛有显著统计学差异(P=0.001)。结论现有临床证据表明,强骨胶囊可改善原发性骨质疏松症患者骨密度、缓解骨痛,但还需要高质量的随机对照试验来进一步验证。Objective To systematically review the efficacy and safety of Qianggu capsule for treatment of primary osteoporosis. Methods Literatures related to Qianggu capsule for osteoporosis treatment in the past 10 years was searched using computer searching system. Data was extracted according to the inclusion and exclusion standard. Meta-analysis was used to systematically review the efficacy and safety, including BMD, bone pain and complications. Results Five literatures were included. Using meta-analysis, it was found that BMD change had statistical difference （ P = 0. 02） before and after Qianggu capsule treatment. Bone pain alleviation had significant statistical difference （P = 0. 001 ）, comparing to traditional drugs. ConclusionCurrent clinical evidence indicates that Qianggu capsule is efficient for increasing BMD in primary osteoporosis and for alleviating bone pain. More high quality randomized control trials are needed for further evidence.

关 键 词：骨质疏松症 强骨 META分析 

分 类 号：R681[医药卫生—骨科学]